Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

Summary

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma

Timeline

Start

2019-06-14

Primary completion

2024-05-24

Completion

2024-08-13

Outcome

Met primary endpoint

registry analysis (superiority test); Tezepelumab 210mg Q4W vs Placebo; p <0.001; Rate Ratio 0.26 (95% CI 0.17 to 0.39); Negative Binomial Regression NCT03927157 ↗

Drugs

Indications